Qure
Founded 2016 Β· 425 employees on LinkedIn Β· 12 known investors
Qure.ai builds deep learning and AI software to detect and manage diseases such as lung cancer, tuberculosis, pediatric TB, and stroke, with several FDA-cleared solutions. It serves clinicians and care teams as well as the pharmaceutical and medical device industries worldwide.
Also known as Qure.ai Β· QURE.AI TECHNOLOGIES LIMITED
Investors Β· 12
Also in the syndicate Β· 4
Funding
SEC filings, press & company announcements- Undisclosed amountSeries DSep 2024 Β· 3 sources
360 ONE Asset (lead), 360One Asset (lead), Lightspeed (lead), Health Quad, Kae Capital, Merck Global Health Innovation Fund, Novo Holdings, TeamFund
Source β
Source: company announcements and press reports β follow each round's link for the claim.
Company profile
researched Aug 2026Qure.ai is a health technology company that applies deep learning to medical imaging so clinicians can identify and manage diseases including tuberculosis, pediatric tuberculosis, silicosis, lung cancer and stroke. Its products interpret X-ray, CT, MR and ultrasound studies, with named solutions including qXR for chest X-rays, qER for brain CT and qCT for chest CT. Outputs are delivered as annotated images and editable full-text reports, and the AI is regulated as a medical device intended for use by trained clinicians.
The portfolio is organised around three clinical pathways: public health screening and disease surveillance for TB and related lung conditions; an end-to-end lung cancer continuum covering early nodule detection, disease-progression measurement and case management; and a stroke care-coordination suite providing triage, real-time communication and hub-and-spoke network support for timely intervention. The company also markets AI biomarkers for clinical trials and works with pharmaceutical and medical device companies. A companion mobile application lets clinicians view multi-modality scans remotely, supports HIPAA-compliant messaging and critical-patient alerting, and collects clinical information for pre-hospital and emergency settings.
As of its Series D announcement, Qure.ai reported 18 FDA-cleared indications and Class IIb certification under EU MDR, and its chest X-ray solution for TB screening received WHO endorsement for use in the absence of a human reader. The company is headquartered in Mumbai with regional offices in New York, London and Dubai; a UK-registered entity, QURE.AI TECHNOLOGIES LIMITED, is listed at an address in Birmingham, United Kingdom.
Founding story
Founded in 2016 by Prashant Warier, who serves as Co-founder and CEO. Warier previously was Chief Data Scientist at Fractal and founded the AI startup Imagna Analytics; he holds a PhD from Georgia Tech and a bachelor's degree from IIT Delhi, holds 30+ patents and has published in The Lancet and Nature.
Business model
Qure.ai sells AI software that layers onto existing imaging hardware at hospitals, care sites and screening programs, and works with pharmaceutical and medical device companies on early diagnosis, clinical trials and AI biomarkers. It states collaborations with half of the top 20 pharma and medtech companies, including AstraZeneca, Medtronic and J&J.
Traction
Qure.ai reports 45M+ lives impacted to date and deployment across 5,500+ sites in 105+ countries on its website; at the September 2024 Series D it cited 3,000+ sites in over 90 countries. A May 2025 speaker biography for the CEO cited 4,000+ hospitals across 100+ countries and over 30 million patient lives impacted. Its mobile app has over 1,000 downloads on Google Play.
Latest developments
In September 2024 Qure.ai completed a $65 million Series D led by Lightspeed and 360 ONE Asset to fund US and international expansion, foundational AI model development and acquisitions of complementary med-tech companies. Around the same period it announced a partnership with Strategic Radiology, launched an FDA-cleared solution for advanced nodule quantification and presented study results at the World Conference on Lung Cancer. It has published a study on real-world impact of its stroke workflow tools, is promoting AI biomarkers for clinical trials, and announced Mihir Bhanushali joining as EVP, Global Health.
βΈFull profile β market position, technology, go-to-market, geography, history
Market position
The company describes itself as the world's most deployed/adopted healthcare AI, and was named to TIME's 100 Most Influential Companies of 2025 and TIME 100 / Statista Top HealthTech Companies. Its investor group includes Lightspeed, 360 ONE Asset, Merck Global Health Innovation Fund, Novo Holdings, HealthQuad, Kae Capital and TeamFund.
Qure.ai emphasises hardware-agnostic deployment that works with existing or older X-ray machines, breadth of regulatory clearances (18 FDA-cleared indications, EU MDR Class IIb, WHO endorsement for TB screening without a human reader), scale of deployment across low- and high-resource settings, and diagnostic sensitivity and specificity that investors describe as rivaling radiologists and physicians.
Technology
Deep learning and artificial intelligence models trained on large imaging datasets (the company cites 1B+ training datasets) that analyse chest X-rays (qXR), brain CT (qER), chest CT (qCT), MR and ultrasound, producing results the company says are available in under a minute. The software is designed to work with both new and older X-ray systems, and the company reports 18 FDA-cleared indications, EU MDR Class IIb certification and a WHO endorsement for TB screening without a human reader.
Go-to-market
Direct sales to hospitals, health systems and national health programmes, strategic partnerships with pharmaceutical and medtech companies (AstraZeneca, Medtronic, J&J) and radiology groups (Strategic Radiology, Medica Group), participation in global health initiatives such as the EDISON Alliance 1 Billion Lives Challenge, and conference presence (for example ASCO). The company recruits for business development, regulatory, clinical research, customer success and engineering roles.
Hospitals and health systems (for example NHS Greater Glasgow and Clyde, Nottingham University Hospitals NHS Trust, Medica Group), national health ministries and TB programmes such as Lesotho's, clinicians and radiologists, and pharmaceutical and medtech companies.
Geography
Headquartered in Mumbai with regional offices in New York, London and Dubai, and a UK entity registered in Birmingham. Deployments span the US, Europe, Asia, Africa and Latin America across 105+ countries.
History
Qure.ai was founded in 2016. It received the Netexplo award in 2017, and in 2018 became the first AI company featured in The Lancet and obtained CE certification for its brain CT product. In 2019 it won the TB Quest Awards supported by India Health Fund. In 2020 it raised Series A funding from Sequoia Capital and Mass Mutual Ventures, received FDA clearance for its brain CT product, launched a COVID-19 AI solution and partnered with AstraZeneca on lung cancer screening. In 2021 it obtained FDA certification for brain CT quantification and WHO endorsement of its chest X-ray TB screening solution, and was featured in CB Insights' most promising health-tech startups. Later recognitions include Small Business Research Initiative Healthcare Funding (2022), Deloitte Technology Fast 50 India category winner and AI Gamechanger first prize (2023), the Siemens Healthineers Startup Award (2024), and TIME 100 Most Influential Companies plus an ET Startup Top Innovator Award (2025). In September 2024 the company closed a $65 million Series D.
Compiled by commissioned research from 8 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Timeline Β· 13
launches, deals, and filingsProceeds earmarked for US and international expansion, investment in foundational AI models and acquisitions of complementary med-tech companies.
$65M source β
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
βΈResearch sources Β· 8
primary sources listed
- Qurequre.ai Β· web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Qure do?
- Qure.ai builds FDA-cleared medical imaging AI for chest X-ray, CT and other scans to detect TB, lung cancer and stroke.
- Who are Qure's investors?
- Qure's investors include Crane Venture Partners, Lightspeed Venture Partners, HealthQuad, Kae Capital, MassMutual Ventures, Merck Global Health Innovation Fund, Novo Holdings, Sequoia Capital.